Patents by Inventor Alexander R. Hurd

Alexander R. Hurd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190175556
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: June 13, 2019
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Publication number: 20180334438
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: March 14, 2018
    Publication date: November 22, 2018
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 10085972
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Patent number: 9932313
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 3, 2018
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9920012
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 20, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Publication number: 20170354643
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 14, 2017
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Publication number: 20170267643
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: February 1, 2017
    Publication date: September 21, 2017
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9707211
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 18, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Patent number: 9580388
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9580391
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Publication number: 20160287559
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: February 4, 2016
    Publication date: October 6, 2016
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Patent number: 9370507
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 21, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • Patent number: 9266839
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 23, 2016
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Publication number: 20160039769
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: July 16, 2015
    Publication date: February 11, 2016
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9221814
    Abstract: The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: December 29, 2015
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood
  • Publication number: 20150335625
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: April 1, 2015
    Publication date: November 26, 2015
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • Patent number: 9169199
    Abstract: The invention provides cycloalkyl guanidine compounds that inhibit F1F0-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: October 27, 2015
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Patent number: 9139532
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 22, 2015
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. Van Huis
  • Publication number: 20150183745
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: December 10, 2014
    Publication date: July 2, 2015
    Applicant: LYCERA CORPORATION
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Publication number: 20150152063
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: June 7, 2013
    Publication date: June 4, 2015
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis